By Dirk Brinckman Chief Compliance Officer, Johnson & Johnson Chair, IFPMA Ethics and Business Integrity Committee Chair, ...
IFPMA submitted a statement at the start of the 17th meeting of the Conference of the Parties to the Convention on Biological ...
This infographic shows how just a 1% increase in seasonal influenza vaccination coverage can deliver substantial health and economic benefits. It highlights influenza’s global disease burden, ...
On 13 October 2026, on the occasion of the adoption of the Political Declaration on Pandemic Prevention, Preparedness, and ...
On 14 September 2026, IFPMA delivered a statement ahead of the eighth meeting of the Intergovernmental Working Group (IGWG 8) on the WHO Pandemic Agreement. One hundred days have passed since the ...
100 days after the Ebola Bundibugyo outbreak was declared in the Democratic Republic of the Congo, the global pharmaceutical industry has underlined its track record and commitment to tackling health ...
On 6 July 2026, IFPMA delivered a statement ahead of the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement. The extension of the negotiations provides an ...
The latest Ebola Bundibugyo outbreak in Democratic Republic of Congo, Uganda, and neighbouring countries is deeply concerning. Pharmaceutical and biotech companies are working with global partners in ...
Against a backdrop of growing geopolitical uncertainty, governments are reassessing what competitiveness and economic security mean in practice. Success critically depends on the ability to identify, ...
As populations age and rates of non-communicable diseases rise across all demographics, adult immunization represents a high-impact and cost-effective investment in economic growth and societal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results